Karen Sepucha, PhD, describes what a good decision is, how we measure decision quality and how the decision quality instrument might be used.
This presentation was part of a Shared Decision Making Month webinar -- What Makes a Good Medical Decision? Defining and Implementing Decision Quality Measures.
Aligning Incentives for Patient Engagement: Enabling Widespread Implementation of Shared Decision Making
May 23, 2013
Karen Sepucha, Massachusetts General Hospital
Dale Collins Vidal, The Dartmouth Institute for Health Policy & Clinical Practice
MedicalResearch.com: Exclusive Interviews with Medical Research and Health Care Researchers from Major and Specialty Medical Research Journals and Meetings
Course 2 the need for a careful and thorough historyNelson Hendler
The medical literature reports that 40%-80% of chronic pain patients are misdiagnosed. Clearly, misdiagnosis leads to ordering the wrong tests, and thereby obtaining an incorrect diagnosis, or overlooking a diagnosis totally, which results in mistreatment. Many reports in the medical literature indicate the best way to get an accurate diagnosis, is to obtain a complete and thorough history. However, this is a time consuming process, and most physicians don’t spend the needed time with a patient. Therefore, a team of doctors from Johns Hopkins Hospital developed a 72 question test, with 2008 possible answers, available over the Internet. When a patient completes the questionnaire, diagnoses are returned within 5 minutes. These diagnoses have a 96% correlation with diagnoses of Johns Hopkins Hospital doctors. This is the highest level of accuracy of any expert system available. The efficacy of this approach is proven by outcome studies, which prove that this approach results in a far higher return to work rate and reduced use of medication and doctors visits, when compared to other techniques. This is similar to the techniques used by Johns Hopkins Hospital to reduce their workers compensation payments by 54%.
Aligning Incentives for Patient Engagement: Enabling Widespread Implementation of Shared Decision Making
May 23, 2013
Karen Sepucha, Massachusetts General Hospital
Dale Collins Vidal, The Dartmouth Institute for Health Policy & Clinical Practice
MedicalResearch.com: Exclusive Interviews with Medical Research and Health Care Researchers from Major and Specialty Medical Research Journals and Meetings
Course 2 the need for a careful and thorough historyNelson Hendler
The medical literature reports that 40%-80% of chronic pain patients are misdiagnosed. Clearly, misdiagnosis leads to ordering the wrong tests, and thereby obtaining an incorrect diagnosis, or overlooking a diagnosis totally, which results in mistreatment. Many reports in the medical literature indicate the best way to get an accurate diagnosis, is to obtain a complete and thorough history. However, this is a time consuming process, and most physicians don’t spend the needed time with a patient. Therefore, a team of doctors from Johns Hopkins Hospital developed a 72 question test, with 2008 possible answers, available over the Internet. When a patient completes the questionnaire, diagnoses are returned within 5 minutes. These diagnoses have a 96% correlation with diagnoses of Johns Hopkins Hospital doctors. This is the highest level of accuracy of any expert system available. The efficacy of this approach is proven by outcome studies, which prove that this approach results in a far higher return to work rate and reduced use of medication and doctors visits, when compared to other techniques. This is similar to the techniques used by Johns Hopkins Hospital to reduce their workers compensation payments by 54%.
SHARE Presentation: Maximizing Treatment Options -- What to Know When Conside...bkling
Current and former clinical trial participants discuss decision-making from a patient's perspective. What factors should you consider when choosing a clinical trial? What are the potential benefits of participating? What misconceptions might discourage people from seeking clinical trials? When is it best not to participate? Panelists include women living with metastatic breast and ovarian cancers.
Presented in:
Pre-Conference Workshop on Communication Skills in Management of Cancer Patients,
World Cancer Day Conference & Expo 2015
by National Cancer Society of Malaysia
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershmanbkling
Dr. Dawn L. Hershman of the Herbert Irving Comprehensive Cancer Center at Columbia University presented the basics of clinical trials and emphasized how important it is for more patients to participate in them. She also discussed trials currently available for early stage and metastatic breast cancers. The webinar was presented on June 25, 2014. To hear the webinar, visit www.sharecancersupport.org/hershman
How We Do Harm: A Webinar by SHARE with Dr. Otis Brawleybkling
Dr. Otis Brawley, author of How We Do Harm, pulls back the curtain on how health care is really practiced in American. Hosted by SHARE: Self-help for Women with Breast or Ovarian Cancer.. www.sharecancersupport.org. If you would like to watch the full webinar, visit www.sharecancersupport.org/brawley.
Title. Does Giving the Doctor a Document Template with the Patient's Own Values and Preferences When Making Decisions about Starting Medication Improves Shared Decision Making?
Presented by BITO, Seiji
@ SMDM2019 postersession
This is a slide show about how including the patient perspective as decisions are made about their health care - improves the quality of care being given in the Medical setting.
SHARE Presentation: Maximizing Treatment Options -- What to Know When Conside...bkling
Current and former clinical trial participants discuss decision-making from a patient's perspective. What factors should you consider when choosing a clinical trial? What are the potential benefits of participating? What misconceptions might discourage people from seeking clinical trials? When is it best not to participate? Panelists include women living with metastatic breast and ovarian cancers.
Presented in:
Pre-Conference Workshop on Communication Skills in Management of Cancer Patients,
World Cancer Day Conference & Expo 2015
by National Cancer Society of Malaysia
SHARE Webinar: Why Should I Join a Clinical Trial with Dr. Hershmanbkling
Dr. Dawn L. Hershman of the Herbert Irving Comprehensive Cancer Center at Columbia University presented the basics of clinical trials and emphasized how important it is for more patients to participate in them. She also discussed trials currently available for early stage and metastatic breast cancers. The webinar was presented on June 25, 2014. To hear the webinar, visit www.sharecancersupport.org/hershman
How We Do Harm: A Webinar by SHARE with Dr. Otis Brawleybkling
Dr. Otis Brawley, author of How We Do Harm, pulls back the curtain on how health care is really practiced in American. Hosted by SHARE: Self-help for Women with Breast or Ovarian Cancer.. www.sharecancersupport.org. If you would like to watch the full webinar, visit www.sharecancersupport.org/brawley.
Title. Does Giving the Doctor a Document Template with the Patient's Own Values and Preferences When Making Decisions about Starting Medication Improves Shared Decision Making?
Presented by BITO, Seiji
@ SMDM2019 postersession
This is a slide show about how including the patient perspective as decisions are made about their health care - improves the quality of care being given in the Medical setting.
Health Care Stories are Good for You
Presented by Sharon Manson Singer, Steve Buist and Jennifer Verma. Canadian Association of Journalists, Annual Meeting, April 28, 2012.
Development of structured orthopedic manual therapy assessment proforma for diagnosing subjects on the basis of orthopedic manual therapy
Authors:Radhika Chintamani*, G. Varadharajulu, Amrutkuvar Rayjade
Int J Biol Med Res. 2024; 15(1): 7735-7740
Abstract:
Background: Proper Diagnosis of orthopedic conditions in the early stage may reduce prevalence of missed diagnosis or wrong diagnosis, thus helping in early and proper intervention and early recovery. Utilizing the highly specified assessment technique for each tissue given in specific manual therapy is limited. Study Design: Validation study to define validity and reliability of Structured Orthopedic Manual Therapy Assessment Proforma. Objective: To analyze the Structured Orthopedic Manual Therapy Assessment Proforma and to assess it’s concurrent validity and reliability. Subjects and Methods: To assess reliability, 100 referred non-operated orthopedic subjects with mean age, 55±2 years were assessed on 2 separate occasions (Group 1). To assess concurrent validity, 200 subjects were assessed with the new format and the old existing format (Group 2). Internal consistency, reproducibility and concurrent validity were determined with Cronbach’s ? coefficient, interclass correlation coefficient and Pearson correlation coefficient, respectively. Results: Cronbach’s ? coefficient for the 10 major domains (Pain, Selective tissue tension testing, Balanced ligamentous tension, Soft tissue assessment, End feel, bony assessment, neural assessment and diagnostic criteria) were high. Intraclass correlation was excellent for all domains along with good concurrent validity and internal consistency. Conclusions: The Structured OMT assessment format outcome instrument has satisfactory internal consistency and excellent reproducibility. It is ready for use in clinical studies on non-operated orthopedic conditions who are capable of physiotherapy treatment. The outcome measure provides a convenient brief measure that can be used to and evaluate and diagnose improvements in Physiotherapy referred subjects with non-operated orthopedic conditions and could potentially be adapted for other painful conditions.
Similar to Measuring and Improving Decision Quality (20)
Do you know where the term “shared decision making” was first used…or when the first center dedicated to its research and implementation was opened? Our infographic “Shared Decision Making through the Decades” will take you on a historical journey through four decades of shared decision making to understand where it is today and what the future might hold.
25 Champions of Shared Decision Making, selected by the staff of the Informed Medical Decisions Foundation. This is not a top 25 list, merely a list of 25 individuals the staff wanted to recognize.
Aligning Incentives for Patient Engagement: Enabling Widespread Implementation of Shared Decision Making
May 23, 2013
Angela Coulter, Informed Medical Decisions Foundation
Dominick Frosch, Gordon and Betty Moore Foundation
Floyd J. Fowler, Informed Medical Decisions Foundation
Aligning Incentives for Patient Engagement: Enabling Widespread Implementation of Shared Decision Making
May 24, 2013
John E. Wennberg, The Dartmouth Institute
Aligning Incentives for Patient Engagement: Enabling Widespread Implementation of Shared Decision Making
May 24, 2013
Jeff Thompson, Washington State Health Care Authority
David Downs, Engaged Public
David Swieskowski, Mercy ACO Mercy Clinics, Inc.
Lisa Weiss, High Value Healthcare Collaborative
Kate Chenok, Pacific Business Group on Health
Aligning Incentives for Patient Engagement: Enabling Widespread Implementation of Shared Decision Making
May 23, 2013
Neil Korsen, MaineHealth
Larry Morrisey, Stillwater Medical Group
Charlie Brackett, Dartmouth-Hitchcock Medical Center
Grace Lin, Palo Alto Medical Foundation
Carmen Lewis, University of North Carolina
Leigh Simmons, Massachusetts General Hospital
Diana Stilwell, MPH, chief production officer at the Informed Medical Decisions Foundation, walks through the role of narratives in decision aids and how the available evidence relates to the Foundation approach.
This presentation was part of a Shared Decision Making Month webinar -- The Power of Narratives: How They Shape the Way Patients Make Medical Decisions.
Jack Fowler, PhD, senior scientific advisor at the Informed Medical Decisions Foundation provides an overview of the Foundation's path to developing decision aids that included patient narratives.
This presentation was part of a Shared Decision Making Month webinar -- The Power of Narratives: How They Shape the Way Patients Make Medical Decisions.
Victoria Shaffer, PhD, describes the the pros and cons of narratives and then explains her work to develop a system of classification for narratives as part of the solution. Victoria provides an overview of the narrative taxonomies she and her colleague have developed.
This presentation was part of a Shared Decision Making Month webinar -- The Power of Narratives: How They Shape the Way Patients Make Medical Decisions.
Floyd J. Fowler Jr, PhD, provides an overview of decision quality measures and the importance of this measurement.
This presentation was part of a Shared Decision Making Month webinar -- What Makes a Good Medical Decision? Defining and Implementing Decision Quality Measures.
David Wennberg, MD, MPH, describes a recent randomized trial he was involved with that studied the potential of shared decision making to reduce costs among preference-sensitive conditions. David also explains the vision of the 20-member High Value Healthcare Collaborative.
This presentation was part of the Shared Decision Making Month webinar "Turning Shared Decision Making Policy into a Reality."
More from Informed Medical Decisions Foundation (20)
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
1. Measuring and Improving
Decision Quality
Karen Sepucha, PhD
Health Decision Science Center
Massachusetts General Hospital
ksepucha@partners.org
http://www.massgeneral.org/decisionsciences/
2. Disclosure
Dr Sepucha receives research and salary
support from Informed Medical Decisions
Foundation
Dr. Sepucha is on the advisory board for Vital
Decisions, LLC
3. Agenda
What is a good decision?
How to measure “decision quality”?
Knowledge
Matching treatment to goals
How might the survey be used?
4. Case study: Mr. M’s Story
71yo man referred to orthopedics, worsening
right hip pain over past 2 years, x-rays confirm
damage
Orthopedic surgeon’s note: “I went over in some
detail different treatment options. He very much
wishes to proceed with right total hip
replacement.”
Talked with family and friends, saw PCP for pre-
op evaluation
4
6. High quality, patient-centered care
NQF
National Quality Forum
Core Themes:
fully informed
treatments reflect patients’
want, needs and preferences
play a key role in making
healthcare decisions
7. Agenda
What is a good decision?
How to measure “decision quality”?
Knowledge
Matching treatment to goals
How might the survey be used?
8. Measuring Decision Quality
To provide evidence that
- The patient understands key
facts.
-The treatment received is
consistent with the patient’s
personal goals.
-The patient was meaningfully
involved in decision making
Sepucha et al. 2004 Health Affairs; Elwyn BMJ 2006
9. Who made the decision about treatment of
your breast cancer?
“they didn’t say to me, “Well, we could
remove the breast, we could do this,
we could do that.” They just said, “This
is what we’re going to do.” And that
Mainly the doctor
was it—I wasn’t in on the decision.”
“She was compassionate, … [and] gave
me the data that I needed ... We talked
statistics and sizes and measurements
X Both equally
and things that helped me..with my
decision.”
“I made the decision. I’m very happy with
the lumpectomy because that’s what I
wanted to do from the beginning. They
Mainly you [my doctors] didn’t disagree. They didn’t
agree. They just said, “Okay.” They
understood.”
10. Survey development process
ITEM GENERATION
Literature review
Focus groups and
interviews
DRAFT INSTRUMENT
Candidate facts and
goals • Draft items
Patient and provider • Cognitive
importance ratings interviews (~n=5)
(~n=20)
• Medical and literacy FINAL INSTRUMENT
review • Formal evaluation,
• Field testing large, diverse
samples
• Benchmarks and
standards for
reporting
11. Field tests across decisions
Surgical decisions (n=1,221)
Breast cancer surgery (n=237, n=445) and Reconstruction (n=84)
Knee and hip osteoarthritis (n=382; n=127)
Herniated disc (n=183)
Cancer screening (n=338)
Colon cancer screening (n=338)
Medication decisions (n=1,243)
Menopause (n=401)
Depression (n=404)
Breast cancer systemic therapy (n=358)
Underserved populations (n=289)
Colon cancer screening, African American (n=191)
Breast surgery Spanish language, HIspanic (n=98)
12. Measuring
knowledge
Key facts
Mix of gist and
quantitative
13. Knowledge scores – discriminant validity
Usual 58%
DVD 69%
Healthy control 41%
Patients 53%
Providers 77%
0 20 40 60 80 100
Sepucha KR, et al. Spine 2012; Sepucha K et al. BMC Musculoskelet Disord 2011 Jul 5;12(1):149; Lee C, et
al. J Am Coll Surg 2012 Jan;214(1):1-10.
14. Do treatments match patients’ goals?
Key outcome in Cochrane systematic review of
patient decision aids
2009 update: 3 studies reported
2011 update: 13 studies reported
Systematic review of concordance methods
(Sepucha and Ozanne 2010)
Variability in definitions
Variability in calculations
Stacey et al. Cochrane Database of Systematic Reviews. 2011, Issue 10. Art. No.: CD001431; Sepucha K and Ozanne E.
Patient Educ Couns 2010 Jan;78(1):12-23. .
15. Measuring
goals
Achieve or avoid
Discriminate among
options
Challenge of timing
assessment
16. Calculating a match
Logistic regression model (treatment
received) with goals as independent
predictors
Model returns predicted probability of having
surgery based on patients’ goals
Considered “match” if probability ≥0.5 and
had surgery or if <0.5 and didn’t
Source: Sepucha K et al. Decision quality instrument for treatment of hip and knee osteoarthritis: a psychometric evaluation. BMC
Musculoskelet Disord 2011 Jul 5;12(1):149.
17. Validity: How well does model reflect
patients’ preferences?
Treatment preference
Non surgical options 40%
Unsure 59%
Surgery 74%
Treatment Preference
Model predicted probability of surgery
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
Model predicted probability, discriminates among those with
different stated treatment preferences, p<0.001 for all comparisons
Source: Sepucha K et al. Decision quality instrument for treatment of hip and knee osteoarthritis: a psychometric evaluation. BMC
Musculoskelet Disord 2011 Jul 5;12(1):149.
18. Do patients get treatments that
match their goals? (n=383)
Had
Had non surgical
Surgery
treatment
Model predicted
Surgery 49% 13%
Model predicted
12% 25%
Non surgical
Those who matched had lower regret and more confidence
Source: Sepucha K et al. Decision quality instrument for treatment of hip and knee osteoarthritis: a psychometric evaluation. BMC
18
Musculoskelet Disord 2011 Jul 5;12(1):149.
19. Is there a “Decision Quality” score?
Composite score
Requires benchmark for considering patients
“informed” (mean of group that watched
decision aid)
Variable across topics, populations
Risk adjustment (e.g. literacy)
20. Agenda
What is a good decision?
How to measure “decision quality”?
Knowledge
Matching treatment to goals
How might the survey be used?
21. What’s the purpose of measurement?
Research Clinical practice Accountability
BasicTranslClinical Care is implemented in Performance
various settings measured and
compared
Detailed Actionable Benchmarks
Theory Feasible Cost/Feasible
Controlled Acceptable Risk adjustment
22. Mr. M’s story, continued
2 years later, pain worsened and night time
pain came back
Went back to surgeon and had replacement
surgery
Good relief of pain, good function, no regrets
23. Summary
Decision quality definition: extent to which patients are informed
and receive treatments match their goals
Well tested survey instruments exist for common topics
Potential uses span research, clinical care, accountability
Research: evaluate different decision support protocols
Diagnostic screen: identify knowledge gaps and goals in advance
of visit
Accountability: documentation required to proceed with elective
surgery
Editor's Notes
We laid out the proposal for for measuring decision quality in a Health affairs article a few years ago. Main concerns were response that focus on guidelines or “setting right rate” that ignored warranted sources fo variation. Instead we wanted to figure out whether the right treatment is being matched with the right patient, to do that you need treatment rates alone are not enough
Three main phases to measure development First item generation – for us that means identifying the key facts and values that are salient for the decisions. TO do this we review clinical evidence for situation, review literature on decision making experiences, run focus groups and patients and providers to learn about their experiences, distill set of candidate facts and values, Those are then rated by samples of patients and providers for importance to select those facts and values that will be included in draft questionnaire. Items in the draft are run through cognitive testing to make sure patients comprehend the questions and responses and that their answers are refelcting what we hope to learn. In addition field testing of the instrument at this phase can help provide some evidence of acceptability (repsonse rates, missing items) test retest and some preliminary validity. Further refinements and formal testing with large diverse samples, result in a final instrument that is ready for widespread use. To date we are in the second phase.